• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Dengue fever vaccine candidate (TAK-003) offers significant protection in trials

byNiki WintersandDeepti Shroff Karhade
November 17, 2019
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In part 1, phase 3 of this randomized controlled trial, the overall vaccine efficacy of TAK-003 (dengue vaccine candidate) was approximately 80% among children ages 4 to 16 years old.

2. In addition, the vaccine increased the number of participants with seropositivity against dengue and showed to have significant efficacy against dengue leading to hospitalizations.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Dengue fever is a mosquito-borne viral illness that causes nausea, vomiting, rash, eye, muscle, joint, and bone pain. It was designated as a top 10 threat to global health in 2019 by the World Health Organization. This study represents a phase of an ongoing randomized trial of a new tetravalent dengue vaccine candidate (TAK-003). Healthy children and adolescents were split into a vaccine group and placebo group. The vaccine group was given two doses over a 3-month period and then virologically tested for the efficacy of preventing dengue fever. The vaccine was more efficacious against dengue fever when compared to the placebo group (0.5 per 100 person-years vs. 2.5 per 100 person-years). In addition, the vaccine group had a lower rate of hospitalizations and was most efficacious against the DENV-2 serotype. This trial is ongoing but is an important step in determining the efficacy of the new TAK-003 vaccine candidate given the global health threat of dengue fever. Further trials are needed to determine long-term safety and efficacy of this vaccine.

Click to read the study in NEJM

Relevant Reading: A recombinant live attenuated tetravalent vaccine for the prevention of dengue

In-Depth [randomized controlled trial]: This double-blind randomized controlled trial is part 1 of phase 3 of the TAK-003 dengue fever vaccine candidate. Part 1 aimed to protect against dengue fever for 12 months after the second vaccine dose. This study included 20,099 children ages 4 to 16 years old from 26 sites around Latin America and Asia. Participants received their first injection between September 2016 and March 2017 and received their second injection 3 months later. Blood specimens were obtained on day 1 before vaccination and day 120 to measure levels of dengue-neutralizing antibodies, and additional testing if the participant presented with a fever or clinically suspected dengue. The vaccine efficacy against all serotypes was 80.2% (95% CI, 73.3 to 85.3; P<0.001). The vaccine had a 97.7% efficacy against DENV-2, 73.7% against DENV01, 62.6% against DENV-3, and inconclusive for DENV-4. The vaccine efficacy against dengue leading to hospitalization was 95.4% (95% CI, 88.4 to 98.2). In addition, 99.5% of participants who were seronegative at baseline had seropositivity 1 month after the second dose of vaccine. Of note, adverse events were similar in the vaccine group and placebo group.

RELATED REPORTS

Wolbachia-infected mosquitos decreased the incidence of symptomatic dengue fever

#VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents

Quick Take: Prior dengue virus infection and risk of Zika: a pediatric cohort in Nicaragua

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Dengue feverDENV-2TAK-003
Previous Post

#VisualAbstract: Previsit Screening for Parental Vaccine Hesitancy

Next Post

Mortality from neurodegenerative disease may be higher among former professional soccer players

RelatedReports

Intrauterine Zika virus infection associated with significant fetal brain abnormalities
Chronic Disease

Wolbachia-infected mosquitos decreased the incidence of symptomatic dengue fever

July 6, 2021
#VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
StudyGraphics

#VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents

December 1, 2019
Intrauterine Zika virus infection associated with significant fetal brain abnormalities
Infectious Disease

Quick Take: Prior dengue virus infection and risk of Zika: a pediatric cohort in Nicaragua

February 1, 2019
Incidence and severity of dengue in pediatric patients higher in Southeast Asia versus Latin America
Chronic Disease

Incidence and severity of dengue in pediatric patients higher in Southeast Asia versus Latin America

March 24, 2016
Next Post
Myeloperoxidase upregulation in epileptogenesis seen on molecular imaging

Mortality from neurodegenerative disease may be higher among former professional soccer players

#VisualAbstract: Metoprolol for the Prevention of Acute Exacerbations of COPD

#VisualAbstract: Metoprolol for the Prevention of Acute Exacerbations of COPD

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Testosterone therapy linked to increased risk of venous thromboembolism

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Hybrid immunity protects against infection with omicron variant of COVID-19
  • #VisualAbstract: Tirzepatide Once Weekly for the Treatment of Obesity
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.